

Datasheet for ABIN7600443 anti-MYT1L antibody (AA 195-825)



	۱۱/	er	٦/	iΔ	۱۸۸
_	ノ V	\sim 1	٧		٧V

Quantity:	100 μg	
Target:	MYT1L	
Binding Specificity:	AA 195-825	
Reactivity:	Human	
Host:	Rabbit	
Clonality:	Polyclonal	
Conjugate:	This MYT1L antibody is un-conjugated	
Application:	ELISA, Western Blotting (WB), Immunofluorescence (IF), Immunocytochemistry (ICC), Flow Cytometry (FACS)	

Product Details

Purpose:	Anti-MYT1L Antibody Picoband®	
mmunogen: E.coli-derived human MYT1L recombinant protein (Position: D195-K825).		
Isotype:	IgG	
Cross-Reactivity (Details):	No cross-reactivity with other proteins.	
Characteristics:	Anti-MYT1L Antibody Picoband® (ABIN7600443). Tested in ELISA, IF, ICC, WB, Flow Cytometry applications. This antibody reacts with Human. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.	
Purification:	Immunogen affinity purified.	

Target Details

Target:	MYT1L
Alternative Name:	MYT1L (MYT1L Products)
Background:	Synonyms: Fascin-2, Retinal fascin, FSCN2
	Tissue Specificity: Localized specifically in the outer and inner segments of the photoreceptor
	cells in the retina.
	Background: Myelin transcription factor 1 like is a protein that in humans is encoded by the
	MYT1L gene. This gene encodes a member of the zinc finger superfamily of transcription
	factors whose expression, thus far, has been found only in neuronal tissues. The encoded
	protein belongs to a novel class of cystein-cystein-histidine-cystein zinc finger proteins that
	function in the developing mammalian central nervous system. Forced expression of this gene
	in combination with the basic helix-loop-helix transcription factor NeuroD1 and the transcription
	factors POU class 3 homeobox 2 and achaete-scute family basic helix-loop-helix transcription
	factor 1 can convert fetal and postnatal human fibroblasts into induced neuronal cells, which
	are able to generate action potentials. Mutations in this gene have been associated with an
	autosomal dominant form of cognitive disability and with autism spectrum disorder. Alternative
	splicing results in multiple variants.
Molecular Weight:	133 kDa
Molecular Weight: Gene ID:	133 kDa 23040
<u> </u>	
Gene ID:	
Gene ID: Application Details	23040
Gene ID: Application Details	23040 Western blot, 0.25-0.5 μg/mL, Human
Gene ID: Application Details	23040 Western blot, 0.25-0.5 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human
Gene ID: Application Details	23040 Western blot, 0.25-0.5 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry (Fixed), 1-3 μg/1x10 ⁶ cells, Human
Gene ID: Application Details	Western blot, 0.25-0.5 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry (Fixed), 1-3 μg/1x10 ⁶ cells, Human ELISA, 0.1-0.5 μg/mL, -
Gene ID: Application Details	Western blot, 0.25-0.5 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry (Fixed), 1-3 μg/1x10 ⁶ cells, Human ELISA, 0.1-0.5 μg/mL, - 1. Blanchet, P., Bebin, M., Bruet, S., Cooper, G. M., Thompson, M. L., Duban-Bedu, B., Gerard, B.,
Gene ID: Application Details	Western blot, 0.25-0.5 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry (Fixed), 1-3 μg/1x10 ⁶ cells, Human ELISA, 0.1-0.5 μg/mL, - 1. Blanchet, P., Bebin, M., Bruet, S., Cooper, G. M., Thompson, M. L., Duban-Bedu, B., Gerard, B., Piton, A., Suckno, S., Deshpande, C., Clowes, V., Vogt, J., Turnpenny, P., Williamson, M. P.,
Gene ID: Application Details	Western blot, 0.25-0.5 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry (Fixed), 1-3 μg/1x10 ⁶ cells, Human ELISA, 0.1-0.5 μg/mL, - 1. Blanchet, P., Bebin, M., Bruet, S., Cooper, G. M., Thompson, M. L., Duban-Bedu, B., Gerard, B., Piton, A., Suckno, S., Deshpande, C., Clowes, V., Vogt, J., Turnpenny, P., Williamson, M. P., Alembik, Y., Clinical Sequencing Exploratory Research Study Consortium, Deciphering
Gene ID: Application Details	Western blot, 0.25-0.5 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry (Fixed), 1-3 μg/1x10 ⁶ cells, Human ELISA, 0.1-0.5 μg/mL, - 1. Blanchet, P., Bebin, M., Bruet, S., Cooper, G. M., Thompson, M. L., Duban-Bedu, B., Gerard, B., Piton, A., Suckno, S., Deshpande, C., Clowes, V., Vogt, J., Turnpenny, P., Williamson, M. P., Alembik, Y., Clinical Sequencing Exploratory Research Study Consortium, Deciphering Developmental Disorders Consortium, Glasgow, E., McNeill, A. MYT1L mutations cause
Gene ID: Application Details	Western blot, 0.25-0.5 µg/mL, Human Immunocytochemistry/Immunofluorescence, 5 µg/mL, Human Flow Cytometry (Fixed), 1-3 µg/1x10 ⁶ cells, Human ELISA, 0.1-0.5 µg/mL, - 1. Blanchet, P., Bebin, M., Bruet, S., Cooper, G. M., Thompson, M. L., Duban-Bedu, B., Gerard, B., Piton, A., Suckno, S., Deshpande, C., Clowes, V., Vogt, J., Turnpenny, P., Williamson, M. P., Alembik, Y., Clinical Sequencing Exploratory Research Study Consortium, Deciphering Developmental Disorders Consortium, Glasgow, E., McNeill, A. MYT1L mutations cause intellectual disability and variable obesity by dysregulating gene expression and development o
Gene ID: Application Details	Western blot, 0.25-0.5 μg/mL, Human Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human Flow Cytometry (Fixed), 1-3 μg/1x10 ⁶ cells, Human ELISA, 0.1-0.5 μg/mL, - 1. Blanchet, P., Bebin, M., Bruet, S., Cooper, G. M., Thompson, M. L., Duban-Bedu, B., Gerard, B., Piton, A., Suckno, S., Deshpande, C., Clowes, V., Vogt, J., Turnpenny, P., Williamson, M. P., Alembik, Y., Clinical Sequencing Exploratory Research Study Consortium, Deciphering Developmental Disorders Consortium, Glasgow, E., McNeill, A. MYT1L mutations cause intellectual disability and variable obesity by dysregulating gene expression and development of the neuroendocrine hypothalamus. PLoS Genet. 13: e1006957, 2017. Note: Electronic Article. 2.

in persons with severe intellectual disability. New Eng. J. Med. 367: 1921-1929, 2012. 3. De

Application Details

7 pplication betalls		
	Rocker, N., Vergult, S., Koolen, D., Jacobs, E., Hoischen, A., Zeesman, S., Bang, B., Bena, F.,	
	Bockaert, N., Bongers, E. M., de Ravel, T., Devriendt, K., and 24 others. Refinement of the critical	
	2p25.3 deletion region: the role of MYT1L in intellectual disability and obesity. Genet. Med. 17:	
	460-466, 2015.	
Restrictions:	For Research Use only	
Handling		
Format:	Lyophilized	
Reconstitution:	Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL.	
Concentration:	500 μg/mL	
Buffer:	Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.	

Storage Comment:

Storage:

4 °C,-20 °C

At -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.

It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freezing and thawing.